A promising drug for an inherited heart risk flops, stunning doctors
Novartis' experimental drug pelacarsen failed to reduce major cardiovascular events in a large study, despite lowering lipoprotein(a) levels. The company will abandon the drug. Results were published in the New England Journal of Medicine, surprising experts who expected positive outcomes. The study involved 8,350 patients over nearly five years, with no significant difference in heart-related events between the treatment and placebo groups.
How this was made
The 30-second read
Why it matters
The negative Phase 3 result removes a potential blockbuster for Novartis and may shift R&D focus toward other cardiovascular programs.
Market read
First‑report of a major trial failure for a large‑cap biotech; likely triggers short‑term sell pressure on NVS and influences sentiment toward Lp(a) drug candidates.
What to watch
The trial showed strong Lp(a) reduction; future combination therapies with LDL‑lowering agents might revive the target.
Background
Pelacarsen was a high‑profile antisense oligonucleotide aimed at reducing lipoprotein(a), a genetic risk factor for heart disease. The drug had previously lowered Lp(a) by ~77% in earlier studies.
Ticker impact
Novartis abandoned pelacarsen after a large Phase 3 trial showed no reduction in major cardiovascular events despite lowering Lp(a) levels.
expected downward pressure as the market prices in the failed trial and potential R&D write‑off.
The trial was the first to test pelacarsen in a large population; its failure removes a major pipeline candidate and may affect future capital allocation.
Market effects
Sets back the broader Lp(a) therapeutic space and may cause investors to reassess other lipid‑lowering biotech stocks.
US biotech sector could see modest pullback; European peers with similar programs may face heightened scrutiny.
Limited to cardiovascular‑drug developers; no immediate macro impact.
Counterpoint
If the trial design or patient selection limited efficacy, a refined next‑generation Lp(a) therapy could still succeed, offering a rebound opportunity for Novartis.
Key entities
- CompanyNovartis
Swiss pharmaceutical giant developing pelacarsen.
- ResearcherDr. Steven Nissen
Lead investigator presenting the trial results.
